DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01782261

CompletedPhase 2

Incretin Effect on the Immunological Phenotype

Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

15

actual

Study population

Healthy volunteers, Type 1 diabetes

Key I/E criterion

•Healthy volunteers

Primary endpoint

•Regulatory FOXP3+ T cells

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01782261
Org study IDADPP004
Secondary ID2011-006300-12

Timeline

Milestones

Study first posted2013-02-01estimated
Last update posted2016-10-11estimated
Study start2012-02 (month precision)
Primary completion2015-02actual (month precision)
Study completion2015-02actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteersType 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age50 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

-healthy subjects or patients with type 1 diabetes

Exclusion criteria

•pregnancy
•treatment with GLP-1-Analoga (Liraglutide, Exenatide)
•treatment with DPP4-inhibitor (Sitagliptin, Vildagliptin, Saxagliptin)
•chronic disease including a long-term medication over 4 weeks per year (except type 1 diabetes)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Increase of regulatory FOXP3+ T cells

Time frame:4 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Immunophenotyping

Time frame:4 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.